DoD tests AI models that make it easy to switch from vendors like Palantir
Investing.com -- Sanofi SA (EPA:SASY) announced Friday that its drug Sarclisa has received approval in the European Union for the treatment of transplant-eligible newly diagnosed multiple myeloma.
The approval extends Sarclisa’s use across all therapy lines in the EU, marking an important expansion of the drug’s treatment scope.
According to the French pharmaceutical company, Sarclisa-VRD demonstrated a significant benefit in minimal residual disease (MRD) negativity, an important measure of treatment effectiveness in multiple myeloma patients.
This regulatory milestone adds to Sarclisa’s existing approvals, now making it available for multiple myeloma patients at various stages of their treatment journey within the European Union.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.